Study designs of evaluations included in the review
Only randomised controlled trials (RCTs) were eligible for inclusion in the review.
Specific interventions included in the review
Studies that assessed the effects of either an angiotensin-converting enzyme inhibitor or a selective angiotensin receptor AT1 blocker, compared with a placebo or other active drug, were eligible for inclusion. The specific interventions in the eligible studies were enalapril, lisinopril, captopril, ramipril, losartan, candesartan and valsartan, all at a variety of dosages. Active comparator drugs were beta-blockers or diuretics, or amlodipine. The mean follow-up ranged from 1 to 6 years.
Participants included in the review
Studies involving data on non-diabetic participants with arterial hypertension or CHF were eligible for inclusion. In the included studies, the mean age of the participants ranged from 52.4 to 76.1 years, the mean body mass index (where reported) ranged from 26.7 to 29.8, and the percentage of participants with diabetes at baseline ranged from 4.8 to 38.9%.
Outcomes assessed in the review
Studies that assessed the incidence of new cases of T2DM and presented the criteria used to define the confirmation of diabetes were eligible for inclusion in the review.
How were decisions on the relevance of primary studies made?
The author did not state how the papers were selected for the review, or how many reviewers performed the selection.